DynamX Coronary Bioadaptor System
Commercial- Indications
- Coronary artery disease
Company intelligence / Profile preview
Elixir Medical
Milpitas, California, United Stateselixirmedical.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Elixir Medical’s DynamX bioadaptor implant has demonstrated significant reductions (>80%) in adverse events compared to best-in-class drug-eluting stents across two randomized controlled trials, with consistent results across geographies and complex patient populations. The LithiX Hertz Contact IVL system recently received CE Mark approval for treating calcified coronary lesions.
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceDrug-device combination (for drug-eluting stents)Mechanical intravascular lithotripsy system
- Industry
- Implantable Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Elixir Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elixir Medical.